- Home
- HON vs GILD Comparison
HON vs GILD Comparison
Compare HON & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HON
- GILD
- Stock Information
- Founded
- HON 1885
- GILD 1987
- Country
- HON United States
- GILD United States
- Employees
- HON N/A
- GILD N/A
- Industry
- HON Aerospace
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HON Industrials
- GILD Health Care
- Exchange
- HON Nasdaq
- GILD Nasdaq
- Market Cap
- HON 124.5B
- GILD 147.6B
- IPO Year
- HON N/A
- GILD 1992
- Fundamental
- Price
- HON $199.15
- GILD $125.33
- Analyst Decision
- HON Buy
- GILD Buy
- Analyst Count
- HON 14
- GILD 22
- Target Price
- HON $249.36
- GILD $122.09
- AVG Volume (30 Days)
- HON 4.9M
- GILD 6.8M
- Earning Date
- HON 10-23-2025
- GILD 10-30-2025
- Dividend Yield
- HON 2.39%
- GILD 2.53%
- EPS Growth
- HON 9.45
- GILD 6514.05
- EPS
- HON 9.47
- GILD 6.42
- Revenue
- HON $40,670,000,000.00
- GILD $29,087,000,000.00
- Revenue This Year
- HON $7.02
- GILD $3.05
- Revenue Next Year
- HON N/A
- GILD $3.29
- P/E Ratio
- HON $21.01
- GILD $19.45
- Revenue Growth
- HON 7.45
- GILD 2.79
- 52 Week Low
- HON $169.05
- GILD $86.08
- 52 Week High
- HON $227.82
- GILD $127.68
- Technical
- Relative Strength Index (RSI)
- HON 43.20
- GILD 62.45
- Support Level
- HON $193.62
- GILD $117.13
- Resistance Level
- HON $203.04
- GILD $127.68
- Average True Range (ATR)
- HON 3.60
- GILD 3.65
- MACD
- HON -0.10
- GILD 0.24
- Stochastic Oscillator
- HON 24.07
- GILD 81.84
About HON Honeywell International Inc.
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).